| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
|
| Targets |
Natural alkaloid
|
|---|---|
| ln Vitro |
Laurolitsine has anti - platelet activity in vitro. At a concentration of 300 μM, it can significantly inhibit the aggregation of rabbit platelets induced by arachidonic acid (100 μM) and collagen (10 μg/ml), and slightly inhibit the aggregation induced by adenosine diphosphate (ADP, 20 μM). It may achieve this by inhibiting thromboxane A2 formation [1]
|
| Cell Assay |
Platelet aggregation assay: Rabbit platelets are isolated and incubated with different concentrations of Laurolitsine. Then, add arachidonic acid, collagen or ADP as inducers. Observe and record the platelet aggregation situation through a turbidimetric method. Measure the change of light transmittance, and draw a curve of the relationship between drug concentration and platelet aggregation rate to evaluate the anti - platelet effect of Laurolitsine [1]
|
| Toxicity/Toxicokinetics |
22179 mouse LD50 oral 450 mg/kg CARDIAC: CHANGE IN RATE; VASCULAR: BP LOWERING NOT CHARACTERIZED IN AUTONOMIC SECTION; LUNGS, THORAX, OR RESPIRATION: OTHER CHANGES Annales Pharmaceutiques Francaises., 38(537), 1980 [PMID:7283352]
22179 mouse LD50 intraperitoneal 170 mg/kg CARDIAC: CHANGE IN RATE; VASCULAR: BP LOWERING NOT CHARACTERIZED IN AUTONOMIC SECTION; LUNGS, THORAX, OR RESPIRATION: OTHER CHANGES Annales Pharmaceutiques Francaises., 38(537), 1980 [PMID:7283352] 22179 mouse LD50 intravenous 90 mg/kg CARDIAC: CHANGE IN RATE; VASCULAR: BP LOWERING NOT CHARACTERIZED IN AUTONOMIC SECTION; LUNGS, THORAX, OR RESPIRATION: OTHER CHANGES Annales Pharmaceutiques Francaises., 38(537), 1980 [PMID:7283352] |
| References | |
| Additional Infomation |
Laurolitsine is an aporphine alkaloid. Together with other aporphine and phenanthrene alkaloids, it is studied for its anti - platelet effect. Its anti - platelet mechanism may be related to the inhibition of thromboxane A2 formation, which is one of the key factors leading to platelet aggregation [1]
Laurolistine is an aporphine alkaloid that is noraporphine substituted by hydroxy groups at positions 2 and 9 and methoxy groups at positions 1 and 10. Isolated from Litsea glutinosa and Lindera chunii, exhibits inhibitory activity against HIV-1 integrase. It has a role as a metabolite and a HIV-1 integrase inhibitor. It is a member of phenols, an aromatic ether and an aporphine alkaloid. It is functionally related to an aporphine. Laurolitsine has been reported in Litsea glutinosa, Neolitsea konishii, and other organisms with data available. |
| Molecular Formula |
C18H19NO4
|
|---|---|
| Molecular Weight |
313.3478
|
| Exact Mass |
313.131
|
| Elemental Analysis |
C, 69.00; H, 6.11; N, 4.47; O, 20.42
|
| CAS # |
5890-18-6
|
| Related CAS # |
Laurolitsine hydrochloride
|
| PubChem CID |
22179
|
| Appearance |
Off-white to pink solid
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
553.0±50.0 °C at 760 mmHg
|
| Melting Point |
138-140ºC
|
| Flash Point |
288.3±30.1 °C
|
| Vapour Pressure |
0.0±1.5 mmHg at 25°C
|
| Index of Refraction |
1.643
|
| LogP |
1.43
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
23
|
| Complexity |
433
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
O(C([H])([H])[H])C1=C(C([H])=C2C([H])([H])C([H])([H])N([H])[C@@]3([H])C([H])([H])C4=C([H])C(=C(C([H])=C4C1=C32)OC([H])([H])[H])O[H])O[H]
|
| InChi Key |
KYVJVURXKAZJRK-LBPRGKRZSA-N
|
| InChi Code |
nChI=1S/C18H19NO4/c1-22-15-8-11-10(7-13(15)20)5-12-16-9(3-4-19-12)6-14(21)18(23-2)17(11)16/h6-8,12,19-21H,3-5H2,1-2H3/t12-/m0/s1
|
| Chemical Name |
(6aS)-1,10-dimethoxy-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-2,9-diol
|
| Synonyms |
Laurolitsine; 5890-18-6; Laurolistine; Norboldine; (+)-Norboldine; (6aS)-1,10-dimethoxy-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-2,9-diol; Dimethoxy-1,10 dihydroxy-2,9 nor-aporphine; 1,10-Dimethoxy-6a-alpha-noraporphine-2,9-diol;
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~319.13 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.1913 mL | 15.9566 mL | 31.9132 mL | |
| 5 mM | 0.6383 mL | 3.1913 mL | 6.3826 mL | |
| 10 mM | 0.3191 mL | 1.5957 mL | 3.1913 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
